Results 121 to 130 of about 920 (164)

Proceedings of the CIMAGO Congress - Environment, Genetics and Oncobiology in the 21st Century - Challenges and Opportunities. [PDF]

Medicine (Baltimore)
europepmc   +1 more source

Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma. [PDF]

Oncoimmunology
Zhang L, Ren S, Lan T, Marco V, Liu N, Wei B, Chen Y, Wu J, Li Q, Wu F, Lu P, Miao J, Lin H, Wang X, Zhong J, Li J, Fan S.   +16 more
europepmc   +1 more source

Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial). [PDF]

ESMO Open
Hwang S, Hong MH, Shin SH, Yun T, Lee KW, Kim JH, Ahn MJ, Keam B, Lee HW, Kim MK, Yun HJ, Kim Y, Kim HJ, Cho SH, An HJ, Oh SY, Park SG, Koh YW, Ahn HK, Kwon JH, Lee YG, Park KU, Hwang IG, Kim SB, Kim S, Kim HR, KCSG TRIUMPH investigators.   +26 more
europepmc   +1 more source

The diagnosis and management of cervical intraepithelial neoplasia in women with a transformation zone type 3 [PDF]

, 2018
Manley, Kristyn
core  

Impact of differentiating between persistent and new infections on colposcopy referral in HPV-positive triage-negative women: results from the NTCC2 study. [PDF]

Infect Agent Cancer
Del Mistro A, Mancuso P, Carozzi F, De Marco L, Bisanzi S, Pompeo G, Ronco G, Gori S, Allia E, Gustinucci D, Frayle H, Iossa A, Cesarini E, Bulletti S, Passamonti B, Viti J, Toniolo L, Venturelli F, Giorgi Rossi P, Benevolo M, NTCC2 Working Group.   +20 more
europepmc   +1 more source

3. L’évaluation du Ki-67 dans les carcinomes mammaires invasifs : comment le double marquage p16/Ki-67 peut-il nous aider ? [PDF]

, 2013
Russet R. Ridder, E.
core  

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. [PDF]

BMC Cancer
Cho BC, Braña I, Cirauqui B, Aksoy S, Couture F, Hong RL, Miller WH, Chaves-Conde M, Teixeira M, Leopold L, Munteanu M, Ge JY, Swaby RF, Hughes BGM.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Evaluation of CINtec PLUS® testing as an adjunctive test in ASC‐US diagnosed SurePath® preparations

Diagnostic Cytopathology, 2011
AbstractThe CINtec PLUS® system is an immunohistochemical cocktail composed of antibodies against p16INK4a (surrogate of HPV infection) and Ki‐67 (proliferation marker) meant to improve the sensitivity and specificity for detecting high‐grade dysplasia (HGD).
Neil, Edgerton, Cynthia, Cohen, Momin T, Siddiqui   +2 more
openaire   +2 more sources

Usefulness of CINtec® PLUS p16INK4a/Ki-67 Double-Staining in Cytological Screening of Cervical Cancer

Acta Cytologica, 2011
<i>Objective:</i> This study evaluated the usefulness of p16^INK4a/Ki-67 as a new biomarker in the diagnosis of human papillomavirus (HPV)-related cervical lesions. <i>Study Design:</i> From 69 women with previous positive cytology, clinician-collected (CC) samples were obtained using a Cervex-Brush®.
Tomomi Yoshida, Takaaki Sano, Tatsuya Kanuma, Hiroshi Inoue, Teruko Itoh, Chiaki Yazaki, Mitsuo Obara, Toshio Fukuda   +7 more
openaire   +1 more source